ImmunityBio (NasdaqGS:IBRX) presented new clinical data on ANKTIVA in advanced non small cell lung cancer and BCG unresponsive non muscle invasive bladder cancer at the 2026 ASCO Annual Meeting. The ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one ...

ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

Revenue-stage biotech penny stocks gain attention as approved products, commercial sales, and market volatility sharpen focus ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of ...

ImmunityBio’s (IBRX) meteoric rise this year has forced short sellers betting against the cancer drug developer to record roughly $492M in paper losses in the first 12 trading days of 2026, Bloomberg ...

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Friday after the company announced overall survival results in its QUILT 3.055 study. ImmunityBio said the QUILT 3.055 trial shows median ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 19, Immunitybio Inc ...

Shiong, executive chairman of ImmunityBio, joins “CUOMO” to discuss the latest developments in the Ebola outbreak. The Ebola ...

ImmunityBio Inc. IBRX stock is up during Wednesday’s premarket session as the company is gaining attention following the FDA’s acceptance of its supplemental Biologics License Application (sBLA) for ...